Humira [Abbott, Eisai] will overtake Remicade [Centocor, Schering-Plough, Mitsubishi Tanabe] as the Crohn's disease market leader by 2012

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 569, 2009-01-10 , pp. 11-11(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: ABT-874, therapeutic use; Adalimumab, therapeutic use; Certolizumab-pegol, therapeutic use; Crohn's-disease, treatment; Decision-Resources; Golimumab, therapeutic use; Healthcare-news; Infliximab, therapeutic use; Natalizumab, therapeutic use; Pharmaceutical-industry; Research-and-development; Ustekinumab, therapeutic use

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$27.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A